Cargando...
Dysphonia after Bevacizumab Rechallenge: A Case Report
Inhibition of vascular endothelial growth factor (VEGF) signaling, an initiator of tumor angiogenesis, inhibits tumor growth and invasion. Bevacizumab, a monoclonal antibody to VEGF, in common use as an adjunct to standard chemotherapy like irinotecan in advanced colorectal cancer, also affects the...
Guardado en:
| Publicado en: | Case Rep Oncol |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
S. Karger AG
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4649738/ https://ncbi.nlm.nih.gov/pubmed/26600773 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000441122 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|